Close Menu

NEW YORK (GenomeWeb) – Castle Biosciences today announced it has secured a $6 million credit facility from Silicon Valley Bank.

The funding will be used to support commercial and clinical activities for the firm's cutaneous melanoma test called DecisionDx-Melanoma for determining the metastatic risk of patients with melanoma, Castle President and CEO Derek Maetzold said in a statement. The financing will also be used for general operations. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.